Cbl-b-IN-29
Cbl-b-IN-29 is an orally active inhibitor of CBL-B. It effectively binds to the active site of CBL-B, thereby inhibiting the function of the immune E3 ubiquitin ligase. Cbl-b-IN-29 can induce the release of IL-2 from Jurkat cells with an EC50 of 159 nM. This compound exhibits significant antitumor efficacy in vivo, showing good tolerance with no adverse effects observed. Cbl-b-IN-29 is applicable in cancer immunotherapy and related studies involving colon cancer and tumor immunotherapy combinations.
Product Specifications
CAS Number
3070411-10-5
Smiles
CN1C ([C@@]2 (C[C@H] (C) C2) C3=CC (=CC=C3) C4=CC=5C (NC4=O) =C ([C@H] (NC6CCCC6) C) C=CC5F) =NN=C1
Molecular Formula
C30H34FN5O
Molecular Weight
499.63
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
abx343238-01 20 µL
Histone H2B Type 1-C/E/F/G/I (HIST1H2BC) Antibody
Sign In for Pricing
View Details abx343238-02 50 µL
Histone H2B Type 1-C/E/F/G/I (HIST1H2BC) Antibody
Sign In for Pricing
View Details